Stocks to Watch: Hims & Hers Health, Chegg, Wah Fu Education Group

Dow Jones
02-25
 

By Connor Hart

 

Hims & Hers Health beat fourth-quarter estimates and guided for better-than-expected revenue in the first quarter and 2025. The telehealth provider logged earnings of 11 cents a share on revenue of $481 million in the recent quarter, nearly doubling its results from last year's comparable frame. It forecast revenue of $2.3 billion to $2.4 billion in 2025. Its weight-loss business, though, could come under pressure after the FDA declared an end to the shortage of popular weight-loss drugs Wegovy and Ozempic and said compounding pharmacies supplying companies like Hims will need to stop making and selling knockoff drugs by May 22 at the latest. Shares fall 18%, to $42.30, in after-hours trading.

Chegg is conducting a review of its business and exploring alternatives, including a sale or privatization, as the provider of individualized learning support to students keeps losing subscribers to AI-enabled rivals. The company, which has hired Goldman Sachs as financial adviser for its review, also said it has filed a complaint in federal court against Google and its parent company Alphabet for allegedly blocking traffic from coming to Chegg. Shares decline 22%, to $1.22, in postmarket trading.

Wah Fu Education Group said it would integrate DeepSeek's artificial-intelligence model to its platform. The Chinese company, which provides online-education and exam-preparation services, said the model will provide AI-based assistants for many of its programs, allowing it to customize learning plans based on students' habits. This customization will help increase retention and improve learning, the company said. Shares climb 68%, to $3, in after-hours trading.

 

Write to Connor Hart at connor.hart@wsj.com

 

(END) Dow Jones Newswires

February 24, 2025 18:49 ET (23:49 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10